Skip to content

MARKER THERAPEUTICS, INC.: 10-K filed 2012-04-16

What MARKER THERAPEUTICS, INC. reported in its annual report filed 2012-04-16 (fiscal FY 2011): 17 published measures, 60 facts as tagged in accession 0001424884-12-000026.

This filing

Form
10-K (annual report)
Filed
2012-04-16
Fiscal period
fiscal FY 2011
Accession
0001424884-12-000026 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All MARKER THERAPEUTICS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2011-12-31340,212USD
At 2010-12-31116,433USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2011-12-31-3,460,360USD
At 2010-12-31-3,866,876USD
At 2009-12-31-1,783,051USD
At 2008-12-31-3,023,373USD
At 2007-12-31-1,674,772USD
At 2006-12-31-3,000,080USD
At 2005-12-31-2,219,748USD
At 2004-12-31-2,440,130USD
At 2003-12-31-643,745USD
At 2002-12-31465,829USD
At 2001-12-31-74,049USD
At 2000-12-31252,228USD
At 1999-12-31100,367USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2011-01-01 to 2011-12-31-2,028,941USD365
1999-07-27 to 2011-12-31-43,722,216USD4541
2010-01-01 to 2010-12-31-3,532,623USD365
2009-01-01 to 2009-12-31-17,348,546USD365
2008-01-01 to 2008-12-31-2,195,939USD366
2007-01-01 to 2007-12-31-3,891,411USD365
2006-01-01 to 2006-12-31-1,304,387USD365
2005-01-01 to 2005-12-31-985,599USD365
2004-01-01 to 2004-12-31-2,683,105USD366
2003-01-01 to 2003-12-31-5,778,905USD365
2002-01-01 to 2002-12-31-2,284,709USD365
2001-01-01 to 2001-12-31-671,986USD365
2000-01-01 to 2000-12-31-935,332USD366
1999-07-27 to 1999-12-31-80,733USD158

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2011-01-01 to 2011-12-31-1,309,867USD365
1999-07-27 to 2011-12-31-14,854,430USD4541
2010-01-01 to 2010-12-31-925,041USD365

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
1999-07-27 to 2011-12-31218,626USD4541

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2011-01-01 to 2011-12-311,536,585USD365
1999-07-27 to 2011-12-3114,899,917USD4541
2010-01-01 to 2010-12-31807,126USD365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
1999-07-27 to 2011-12-31204,747USD4541

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2011-01-01 to 2011-12-311,261,983USD365
1999-07-27 to 2011-12-3110,675,392USD4541
2010-01-01 to 2010-12-312,146,293USD365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2011-01-01 to 2011-12-31-3,316,189USD365
1999-07-27 to 2011-12-31-35,269,096USD4541
2010-01-01 to 2010-12-31-5,472,231USD365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2011-12-31307,921USD
At 2010-12-3125,299USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2011-12-313,800,572USD
At 2010-12-313,983,309USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2011-01-01 to 2011-12-31203,725USD365
1999-07-27 to 2011-12-315,911,165USD4541
2010-01-01 to 2010-12-31290,048USD365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2011-12-3152,073,460shares
At 2010-12-3140,256,027shares

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2011-12-31-60,528USD
At 2010-12-31-60,895USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2011-01-01 to 2011-12-31305,714USD365
1999-07-27 to 2011-12-312,917,236USD4541
2010-01-01 to 2010-12-31203,066USD365

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
1999-07-27 to 2011-12-31213,227USD4541

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2011-01-01 to 2011-12-31683,450USD365
1999-07-27 to 2011-12-3110,305,575USD4541

Inspect the source

Entity
MARKER THERAPEUTICS, INC. / CIK 0001094038
Captured
2026-09-20T05:22:11.393Z
SEC response SHA-256
11a45295baae8ad4450041d3d51c2454c6531734b6bbb806e124ea5eb0db02da

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001094038.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))